Myomo

Myomo Operating Cash Flow

The Operating Cash Flow of Myomo (MYO) as of Nov 1, 2026 is -14.51 M USD. In the previous year, Operating Cash Flow was -3.29 M USD — a change of 341.09% (lower).

Operating Cash Flow

-14.51 MUSD

YoY

341.09%

Last updated:

Operating Cash Flow of Myomo is 2025 -14.51 M USD. Operating Cash Flow of Myomo was 2024 -3.29 M USD. It decreases by 341.09% lower compared to the previous year.

The Myomo Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-9.61 M USD
Jan 1, 2019
-10.34 M USD
Jan 1, 2020
-9.03 M USD
Jan 1, 2021
-9.55 M USD
Jan 1, 2022
-10.23 M USD
Jan 1, 2023
-6.17 M USD
Jan 1, 2024
-3.29 M USD
Jan 1, 2025
-14.51 M USD
The Myomo Operating Cash Flow history
YEAROperating Cash FlowYoY
-14.51 MUSD+341.09%
-3.29 MUSD-46.70%
-6.17 MUSD-39.68%
-10.23 MUSD+7.18%
-9.55 MUSD+5.70%
-9.03 MUSD-12.66%
-10.34 MUSD+7.66%
-9.61 MUSD+56.11%
-6.15 MUSD+92.13%
-3.20 MUSD-3.95%
-3.33 MUSD+30.92%
-2.55 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myomo Stock analysis

What does Myomo do? Myomo, Inc. generates revenue by selling its MyoPro product line, which consists of myoelectric-controlled upper limb braces designed for patients with neuromuscular disorders. The company directly sells these orthoses to patients and bills their insurance providers for coverage. The MyoPro enables users to control partially paralyzed limbs using their own muscle signals, supporting daily activities like eating and dressing. The target market includes adults and adolescents with conditions such as stroke, spinal cord injury, and brachial plexus injury. The MyoPro product line is marketed as a solution for functional improvement in upper limb paralysis, focusing on home and community use. Myomo’s devices are positioned to help patients regain independence in daily living tasks. Insurance reimbursement is a key revenue stream, with the company handling billing directly to insurers on behalf of patients. The primary customer segments are individuals with neuromuscular conditions requiring orthotic support for upper limb functionality. Myomo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myomo stock

Operating Cash Flow of Myomo is -14.51 M USD in 2025.

Operating Cash Flow of Myomo changed from -3.29 M USD to -14.51 M USD, representing a 341.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Myomo since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Myomo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Myomo

All Key Metrics — Myomo